Patents by Inventor Fronziska Ruchti

Fronziska Ruchti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prevention of cell migration initiation with CMV US28 receptor antagonists
    Publication number: 20020164579
    Abstract: There is disclosed an assay system for determining therapeutic activity for treating restenosis, atherosclerosis, chronic rejection syndrome and graft versus host disease (GVHD) by measuring inhibition of cell migration activity in smooth muscle cells expressing a US28 receptor from the CMV genome. Specifically, there is disclosed a method for measuring inhibition of cell migration in isolated cells transfected with US28 or infected with CMV and stimulated with a ligand. There is further disclosed a method for treating atherosclerosis, restenosis, chronic rejection syndrome and graft versus host disease (GVHD), comprising administering an effective amount of an agent that is a US28 receptor antagonist, wherein a US28 receptor antagonist comprises an inhibitor compound that prevents transduction of US28 receptor signal stimulated by a US28 receptor ligand, wherein a US28 receptor ligand is selected from the group consisting of RANTES, MIP-1&agr; and MCP.
    Type: Application
    Filed: January 11, 2002
    Publication date: November 7, 2002
    Inventors: Jay Nelson, Daniel Streblow, Cecilia Soderberg-Naucler, Patricia Smith, Fronziska Ruchti
  • Prevention of cell migration initiation with CMV US28 receptor antagonists
    Patent number: 6420121
    Abstract: There is disclosed an assay system for determining therapeutic activity for treating restenosis, atherosclerosis, chronic rejection syndrome and graft versus host disease (GVHD) by measuring inhibition of cell migration activity in smooth muscle cells expressing a US28 receptor from the CMV genome. Specifically, there is disclosed a method for measuring inhibition of cell migration in isolated cells transfected with US28 or infected with CMV and stimulated with a ligand. There is further disclosed a method for treating atherosclerosis, restenosis, chronic rejection syndrome and graft versus host disease (GVHD), comprising administering an effective amount of an agent that is a US28 receptor antagonist, wherein a US28 receptor antagonist comprises an inhibitor compound that prevents transduction of US28 receptor signal stimulated by a US28 receptor ligand, wherein a US28 receptor ligand is selected from the group consisting of RANTES, MIP-1&agr; and MCP.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: July 16, 2002
    Assignee: Oregon Health Sciences University
    Inventors: Jay Nelson, Daniel Streblow, Cecilia Soderberg-Naucler, Patricia Smith, Fronziska Ruchti